Choosing the next option: a scenario-based roadmap for b/tsDMARD sequencing in rheumatoid arthritis.
Biologic (b) and targeted synthetic (ts) DMARDs have expanded rheumatoid arthritis (RA) treatment options, but evidence guiding sequencing after b/tsDMARD failure remains heterogeneous and difficult to translate into clinical practice. To provide a pragmatic, scenario-based synt…